骨髓腔内途径脐血与间质干细胞共移植对造血重建的实验研究

目的：探讨骨髓腔内输注（IBM）脐血与间质干细胞（MSCs）对大鼠造血重建、骨髓MSCs恢复的影响，并研究供体MSCs植入状态以探讨MSCs的作用机制。方法：BrdU标记F344大鼠骨髓MSCs通过双侧胫骨IBM或尾静脉注射（IV）与胎鼠及新生大鼠外周血（FNPB）共移植Wistar雌鼠。监测受鼠存活状况、造血免疫重建、HSCs植入水平及骨髓MSCs恢复情况，并以免疫荧光法检测受鼠骨髓MSCs的来源。结果：(1)2个共移植组60 d存活率均为100%，单纯FNPB移植组仅为66.7%。(2)共移植组的外周血象、骨髓造血干祖细胞集落产率明显高于单纯FNPB移植组，尤以骨髓腔共移植组最佳。(3)2个共移植组的HSCs植入水平无统计学差异，而骨髓腔共移植组明显高于单纯FNPB移植组（P＜0.05）。(4)30 d时各移植组MSCs的增殖能力未达正常水平，但仍以骨髓腔共移植组的恢复情况最佳（P＜0.05）。(5)仅少部分受体可发现供、受体源性MSCs嵌合。 结论：脐血与MSCs共移植可促进受体骨髓MSCs恢复和造血重建，提高HSCs植入率；IBM途径应用安全，促进造血恢复的作用优于IV途径。     

小鼠同种异基因骨髓腔内骨髓移植促进早期造血功能重建

目的探讨同种异基因骨髓腔内骨髓移植(IBM-BMT)对小鼠早期造血功能重建的影响。方法将BALB/c小鼠骨髓单个核细胞(BMNCs)分别用胫骨骨髓腔内注射(IBMI)和尾静脉注射(IV)两种方法移植入经致死量60Coγ射线辐照后的60只C57BL/6小鼠。受鼠随机分为3组:骨髓腔内注射高和低剂量组(IBM1和IBM2组)、尾静脉注射组(IV组),每组20只。在骨髓移植后1、3、6和9d分别计数各组受鼠胫骨骨髓腔内有核细胞总数,并用流式细胞术检测供体植入水平(供体来源有核细胞总数、供体来源髓系细胞数)。结果于移植后6d,IBM1组和IBM2组注射侧胫骨骨髓腔内有核细胞总数、供体来源有核细胞总数、供体来源髓系细胞总数均明显高于IV组(P<0.05或P<0.01?。结论IBM-BMT较IV-BMT更能促进同种异基因骨髓移植后的早期造血功能重建。     

IL-3、IL-6联合转基因的基质细胞促进异基因小鼠骨髓移植后的免疫重建

探讨转染IL 3和IL 6基因的骨髓基质细胞系QXMSC1对异基因骨髓移植 (BMT )小鼠免疫功能重建的促进作用。用逆转录病毒载体将小鼠IL 3和IL 6基因转染到骨髓基质细胞系QXMSC1(H 2 d) ,分别建立基质细胞系QXMSC1IL 3、QXMSC1IL 6及QXMSC1IL 3/IL 6 ,供体BALB/c(H 2 d)小鼠骨髓去除T细胞 ,致死量照射 (9 0Gy)受体小鼠C5 7BL/ 6 (H 2 b)后 ,输入供体骨髓细胞 (1× 10 5/只 )的同时输入基质细胞QXMSC1IL 3/IL 6 (5× 10 5/只 )。在骨髓移植后 30d、 6 0d ,检测BMT小鼠脾细胞对LPS、ConA的反应强度、脾细胞中辅助性T淋巴细胞前体频数 (HTLp )、杀伤性T淋巴细胞前体频数 (CTLp )、抗体生成细胞 (PFC )的能力及对迟发型超敏反应 (DTH )的能力来评价BMT后免疫功能的恢复情况。异基因BMT并输入基质细胞系QXMSC1IL 3/IL 6可明显增强BMT后淋巴细胞对LPS、ConA反应强度 ,小鼠对异基因小鼠脾细胞DTH反应增强 ,脾淋巴细胞HTLp、CTLp及PFC数明显增加。基质细胞QXMSC1可作为有效的基因载体明显促进异基因骨髓移植小鼠免疫功能重建。联合转入IL 3和IL 6对BMT后免疫功能的恢复有协同作用     

混合骨髓移植后过继免疫治疗小鼠白血病

背景：急性白血病自体造血干细胞移植后复发率高,异基因造血干细胞移植后移植相关病死率高,混合造血干细胞移植及移植后过继免疫治疗有可能取长补短,提高疗效。 目的：观察自体骨髓混合H-2半相合异体骨髓移植后供体淋巴细胞输注+白细胞介素2治疗对小鼠白血病的疗效。 方法：将Balb/c小鼠经直线加速器照射3 Gy后分为白血病模型组、白血病模型照射组、混合移植组、自体骨髓移植组,均尾静脉注射5×10⁵ K562(GFP+/NeoR+)或K562(GFP-/NeoR-)细胞。7 d后6 Gy照射,自体骨髓移植组移植自体骨髓细胞或联合白细胞介素2治疗;混合移植组移植小鼠自体骨髓细胞混合1/10的H-2半相合异体骨髓细胞后应用白细胞介素2或联合供体淋巴细胞输注治疗。4周后行小鼠外周血及骨髓细胞形态检查,外周血细胞亚群、GFP及NeoR基因测定,肝、脾匀浆细胞GFP和NeoR基因测定。 结果与结论：白血病模型组小鼠因骨髓造血功能衰竭于20 d内全部死亡,白血病模型照射组小鼠因造血功能衰竭于14 d内全部死亡;自体骨髓移植组、混合移植组均有多少不等小鼠无白血病存活超过28 d,且混合骨髓移植后及自体骨髓移植后应用白细胞介素2治疗可提高白血病小鼠长期无病生存率,在此基础上联合供体淋巴细胞输注可更进一步提高白血病小鼠长期无病生存率。     

骨髓腔内输注脐带血及间充质干细胞对大鼠免疫重建影响

目的探讨骨髓腔内（IBM）输注脐带血及骨髓间充质干细胞（BMSC）对移植后大鼠免疫重建的影响。方法雌性F344胎鼠及新生鼠外周血（FNPB）及雄性F344大鼠BMSC共移植经致死量60Coγ射线辐照的雌性Wistar大鼠,其中FNPB均由IBM输注,BMSC则通过IBM或尾静脉（IV）注射。观察受鼠存活状况、供体造血干细胞（HSC）植入水平、免疫细胞及功能恢复、移植物抗宿主病（GVHD）表现,并用PCR检测受鼠供体BMSC来源Y染色体。结果两共移植组60d均100%存活,生存率和供体HSC植入水平差异无统计学意义,但明显优于单纯FNPB移植组;骨髓腔共移植组外周血白细胞及粒单系细胞集落形成单位（CFU-GM）、混合集落形成单位（CFU-GEMM）集落产率恢复较快,14d显著高于其他组（P〈0.05）。而单纯FNPB移植组各检测时点集落计数均明显低于共移植组（P〈0.05）,30dCD19＋细胞比例亦明显低于正常;30d各移植组PHA、LPS诱导淋巴细胞增殖实验及单向混合淋巴细胞培养无明显差异;60d两共移植组存活受鼠均检测到供体BMSC来源Y染色体。结论 HSC与BMSC联合输注可促进受者免疫重建,尤以IBM输注为佳。     

同种反应性自然杀伤细胞对小鼠单倍体骨髓移植后T细胞重建的影响

目的探讨同种反应性自然杀伤（NK）细胞对小鼠单倍体骨髓移植（BMT）后T细胞重建的可能影响。方法以（C57BL/6×BALB/c）BCF1（H-2d/b）为供鼠,BALB/c（H-2d）为受鼠,鼠龄6～8周,体质量16～20 g。建立小鼠单倍体BMT模型。根据移植物不同将实验分为单纯BMT组、非同种反应性NK（non-alloNK）细胞组、同种反应性NK（allo-NK）细胞组,移植后不同时间点以外周血CD3e的表达、外周血血清白细胞介素4（IL-4）、干扰素（IFN-γ）浓度等指标评价同种反应性NK细胞对T细胞重建的可能影响。结果移植后＋10 d受鼠外周血CD3e的表达allo-NK组较non-alloNK组显著增高,分别为（16.58±5.77）%、（8.64±3.60）%,差异具有统计学意义（P〈0.05）。＋30 d时allo-NK组IL-4的浓度显著低于单纯BMT组,分别为（9.73±2.08）pg/mL、（12.44±1.57）pg/mL,差异具有统计学意义（P〈0.05）。non-alloNK组IFN-γ的浓度显著高于单纯BMT组,分别为（98.78±33.07）pg/mL、（52.15±18.87）pg/mL,差异具有统计学意义（P〈0.05）。结论同种反应性NK细胞用于单倍体BMT小鼠,可能促进T细胞的重建,体内诱导Th1免疫反应的偏移。     

可调控表达IL-2基因骨髓基质细胞促进异基因骨髓移植小鼠免疫功能重建

目的　探讨可调控表达IL 2基因的骨髓基质细胞系对异基因骨髓移植小鼠免疫功能重建的促进作用。方法　构建四环素诱导的表达小鼠IL 2基因的逆转录病毒载体 ,转染包装细胞PT6 7,感染骨髓基质细胞系QXMSC1(H 2 d) ,构建可诱导表达IL 2基因的工程化骨髓基质细胞系QXM SC1tet on IL 2。受体小鼠C5 7BL 6 (H 2 b)经γ射线致死剂量照射后 ,输入供体BALB c(H 2 d)骨髓细胞1× 10 7 只 (去除T细胞 ) ,同时输注骨髓基质细胞QXMSC1tet on IL 2 5× 10 5 只。灌服多西环素 (Dox)诱导IL 2表达。于骨髓移植 (BMT)后 30d、6 0d检测小鼠脾细胞对ConA的反应强度 ,空斑形成细胞(PFC)数和迟发型超敏反应 (DTH) ,脾细胞中T辅助细胞前体频数 (HTLp)及移植后小鼠脾脏T细胞亚群CD4 + CD8+ 的比值 ,评价BMT后免疫功能的恢复情况。结果　成功建立四环素诱导IL 2基因表达的基因工程化骨髓基质细胞系QXMSC1tet on IL 2。异基因BMT、联合输注QXMSC1tet on IL 2能显著提高BMT小鼠脾细胞对ConA的反应 ,增加脾脏淋巴细胞HTLp及PFC数目 ,并使DTH反应增强 ,改善小鼠脾脏T细胞亚群CD4 + CD8+ 的比值。结论　共输注可调控表达IL 2基因的骨髓基质细胞可促进异基因移植小鼠免疫功能重建。     

转染IL-6基因骨髓基质细胞系对骨髓移植后免疫功能重建的促进作用

目的　探讨转染IL 6基因的骨髓基质细胞系对同基因骨髓移植 (BMT)后小鼠免疫功能重建的促进作用。方法　将IL 6cDNA片段连接到pcDNA3真核表达载体上。用脂质体将pcD NA3IL 6转入骨髓基质细胞系QXMSC1,ELISA法测定转染IL 6基因骨髓基质细胞QXMSC1IL 6培养上清中IL 6的含量 ,有限稀释挑选多个细胞克隆 ,选择表达量最高的转基因细胞系QXMSC1IL 6用于动物实验。BABL c小鼠经γ射线致死量照射后 ,输入同基因骨髓细胞 (10 7 只 )同时输入骨髓基质细胞QXMSC1IL 6 (5× 10 5 只 )。在骨髓移植后 30d、6 0d检测BMT小鼠淋巴细胞对LPS ,ConA增殖反应 ,T辅助细胞前体 (helpTlymphocyteprecursor,HTLp) ,杀伤性T细胞前体 (cytotoxicTlymphocyteprecursor,CTLp) ,迟发型超敏反应 (delayed typehypersensitivity ,DTH)及空斑形成细胞数 (plaqueformingcell,PFC) ,反映骨髓移植后小鼠免疫功能。结果　成功构建pcDNA3IL 6重组体。该细胞体外培养 2 4h分泌IL 6的含量为 11.15 (± 2 .4 1) μg 10 6 。QXMSC1IL 6细胞系能明显增强BMT后淋巴细胞对LPS、ConA反应性 ,小鼠对异基因小鼠脾细胞DTH反应增强 ,脾脏中HTLp ,CTLp及PFC数明显增加。转入外源IL 6cDNA基因的骨髓基质细胞系QXMSC1IL 6在体内能明显促进BMT后小鼠T、B淋巴     

同基因造血干细胞移植免疫重建诱导小鼠皮肤移植耐受

背景：器官移植耐受的最佳效果是能够诱导对移植抗原的特异性免疫耐受。 目的：探讨小鼠异基因皮肤移植后,通过受体同基因造血干细胞移植重建免疫系统诱导移植皮肤免疫耐受的可行性。 方法：取BALB/c小鼠骨髓。以C57BL/6小鼠为供体,BALB/c小鼠为受体,进行异基因皮肤移植;32只受体鼠随机均分为4组：移植对照组、环孢素A组、照射组和骨髓移植组。 结果与结论：照射组小鼠10 d内全部死亡,外周血白细胞数呈持续性降低;而骨髓移植组小鼠长期存活,白细胞数全身照射后6 d降到最低,之后持续性增高,照射后21 d与环孢素A组比较差异无显著性意义(P > 0.05),移植皮肤存活时间显著长于其他各组(P < 0.01),其淋巴细胞浸润及组织结构破坏明显减少,小鼠脾细胞对供体小鼠脾细胞增殖反应显著降低。说明同基因骨髓细胞移植重建免疫系统可显著延长小鼠移植皮肤存活时间,可诱导供者特异性免疫耐受。     

大鼠皮肤移植排异反应中T淋巴细胞亚群的观察

为了了解在皮肤移植组织排异反应中浸润的不同T淋巴细胞亚群 ,分析其与排异反应的关系。采用HE及免疫组化方法观察大鼠III度烫伤后 2 0例同种异体 自体皮肤混合移植和 15例大张同种异体皮肤移植组织在移植后 4或 5、 7、 14、 2 1和 2 8d时CD4+ 和CD8+ 淋巴细胞的比例。结果表明同种异体 自体皮肤混合移植组 7～ 14d时CD8+ 淋巴细胞明显高于大张同种异体皮肤移植组 (P <0 0 5 ) ,在移植后 4或 5dCD4+ 淋巴细胞明显高于CD8+ 淋巴细胞。大张同种异体皮肤移植组在移植后 7～ 14dCD4+ 淋巴细胞明显高于CD8+ 细胞 ,在植皮后 7～ 2 8d高于同种异体 自体皮肤混合移植组 ,2 1d时差异有统计学意义 (P <0 0 5 )。在 7～ 14d时CD4/CD8比值高于同种异体 自体皮肤混合移植组 (P <0 0 5 )。提示同种异体 自体皮肤混合移植排异反应以CD8+ 淋巴细胞为主 ,而在大张同种皮肤移植排异反应中CD4+ 淋巴细胞起主要作用。     

供者源性的骨髓间质干细胞对急性移植物抗宿主病的影响

目的:采用大鼠骨髓移植模型探讨共移植供者源性的骨髓间质干细胞(MSCs)对骨髓移植后急性移植物抗宿主病(GVHD)的影响。方法:体外培养Fisher344大鼠骨髓间质干细胞,扩增至第5代用于移植。建立大鼠异基因急性GVHD模型(F344→Wistar)。受者Wistar大鼠采用致死性全身照射预处理,当天移植F344大鼠骨髓细胞和脾细胞。实验组则移植F344大鼠骨髓细胞、脾细胞和第5代的MSCs。观察各组移植后急性GVHD的发生时间、发病率和存活时间。结果:共移植MSCs推迟急性GVHD的发病时间,延长该组的存活时间,但无法完全消除急性GVHD的发生。结论:MSCs在体内具有免疫抑制功能,供者来源的MSCs在不使用免疫抑制剂情况下,可推迟急性GVHD的发病时间和延长受者的存活时间。     

Intra-bone marrow injection of donor bone marrow cells suspended in collagen gel retains injected cells in bone marrow, resulting in rapid hemopoietic recovery in mice

We have recently developed an innovative bone marrow transplantation (BMT) method, intra-bone marrow (IBM)-BMT, in which donor bone marrow cells (BMCs) are injected directly into the recipient bone marrow (BM), resulting in the rapid recovery of donor hemopoiesis and permitting a reduction in radiation doses as a pretreatment for BMT. However, even with this IBM injection, some of the injected BMCs were found to enter into circulation. Therefore, we attempted to modify the method to allow the efficient retention of injected BMCs in the donor BM. The BMCs of enhanced green fluorescent protein transgenic mice (C57BL/6 background) were suspended in collagen gel (CG) or phosphate-buffered saline (PBS), and these cells were then injected into the BM of irradiated C57BL/6 mice. The numbers of retained donor cells in the injected BM, the day 12 colony-forming units of spleen (CFU-S) counts, and the reconstitution of donor cells after IBM-BMT were compared between the CG and PBS groups. The number of transplanted cells detected in the injected BM in the CG group was significantly higher than that in the PBS group. We next carried out CFU-S assays. The spleens of mice in the CG group showed heavier spleen weight and considerably higher CFU-S counts than in the PBS group. Excellent reconstitution of donor hemopoietic cells in the CG group was observed in the long term (>100 days). These results suggest that the IBM injection of BMCs suspended in CG is superior to the injection of BMCs suspended in PBS.     

Cotransplanted bone marrow derived mesenchymal stem cells (MSC) enhanced engraftment of hematopoietic stem cells in a MSC-dose dependent manner in NOD/SCID mice

Transplantation of marrow-derived mesenchymal stem cells (MSCs), expanded by culture in addition to whole bone marrow, has been shown to enhance engraftment of human hematopoietic stem cells (HSCs). Our hypothesis was that there might be an optimum ratio range that could enhance engraftment. We examined the percent donor chimerism according to the ratio of HSCs to MSCs in non-obese diabetic/severe combined immunodeficiency (NOD/SCID) mice. We tested a series of ratios of co-transplanted CD34(+) -selected bone marrow cells, and marrow-derived MSCs into sublethally irradiated NOD/SCID mice. In all experiments, 1x10(5) bone marrow derived human CD34(+) cells were administered to each mouse and human MSCs from different donors were infused concomitantly. We repeated the procedure three times and evaluated engraftment with flow cytometry four weeks after each transplantation. Serial ratios of HSCs to MSCs were 1:0, 1:1, 1:2 and 1:4, in the first experiment, 1:0, 1:1, 1:2, 1:4 and 1:8 in the second and 1:0, 1:1, 1:4, 1:8 and 1:16 in the third. Cotransplantation of HSCs and MSCs enhanced engraftment as the dose of MSCs increased. Our results suggest that the optimal ratio of HSCs and MSCs for cotransplantation might be in the range of 1:8-1:16; whereas, an excessive dose of MSCs might decrease engraftment efficiency.     

人参二醇组皂苷对再生障碍性贫血小鼠造血组织MAPK/ERK信号通路的诱导作用

目的:观察人参二醇组皂苷(PDS)对免疫介导型再生障碍性贫血(简称再障)小鼠骨髓细胞MAPK/ERK信号通路蛋白激酶及脾脏调节性T细胞的诱导作用,探讨其治疗再障的作用机制。方法:用[60Co]-γ射线5.0 Gy全身照射BALB/c小鼠,后经尾静脉输入DBA/2小鼠的淋巴细胞悬液,制备免疫介导型再障小鼠模型。60只小鼠随机分为6组,即正常组,模型组,PDS低、中、高剂量组,环孢素组。不同浓度药物灌胃治疗14 d测定各组小鼠外周血象,观察骨髓病理切片,Western blot法及免疫组织化学法测定骨髓细胞MEK1/2、p-MEK1/2、ERK1/2和p-ERK1/2的蛋白水平,流式细胞术检测脾脏调节性T细胞比例。结果:再障小鼠外周血全血细胞减少,骨髓呈抑制状态;PDS治疗能够显著升高再障小鼠外周血象,增加脾脏调节性T细胞比例,呈剂量依赖性(P0.05)。PDS中、高剂量组显著上调骨髓细胞MEK1/2、p-MEK1/2、ERK1/2和p-ERK1/2的蛋白水平(P0.05)。结论:PDS能有效促进造血,上调再障模型小鼠骨髓细胞MAPK/ERK信号通路多种蛋白激酶的表达,可能是PDS促进骨髓造血功能恢复的作用机制之一。另外,PDS对再障模型小鼠的免疫功能有一定的调节作用。     

Distinct phases in recovery of reconstituted innate cellular-mediated immunity after murine syngeneic bone marrow transplantation.

Defects in immune reconstitution after hematopoietic stem cell transplantation confer extreme infection risk on to the transplant recipient. Perturbations in adaptive immune reconstitution have been well characterized, yet defects in reconstituted innate cellular-mediated immunity remain largely unstudied. Recovery in innate effector cells was defined by using an established murine model of autologous bone marrow transplantation. Cytokine induction after cell culture and systemic stimulation with pathogen-associated molecular patterns was also measured for control, transplant-recipient, and irradiated-only animals. Early reconstitution (7 to 14 days) of donor-derived macrophages, dendritic cells, and polymorphonuclear cells was associated with recovery in interleukin (IL)-12p70 and IL-6 production. Later reconstitution (21 days) of natural killer cells was associated with interferon (IFN)-gamma recovery. Hence, splenocyte innate cellular-mediated immunity recovered to normal levels in cellularity and IL-12p70, IFN-gamma, and IFN-alpha production by 21 days after transplantation. In contrast, levels of systemic cytokine production from transplant-recipient and irradiated-only animals were preserved despite incomplete or absent hematopoietic reconstitution. These results suggest that innate immune responses to systemic inflammatory challenges are largely intact after autologous bone marrow transplantation, whereas local innate cellular-mediated immunity within reconstituting lymphoid organs may be impaired. The disparate effects of autologous hematopoietic stem cell transplantation on host immune function may translate to differences in susceptibility to local versus systemic infectious challenges.     

骨髓间充质干细胞对致敏小鼠造血干/祖细胞移植植入的影响

目的: 前期的研究已经证实致敏小鼠造血干/祖细胞移植植入失败率高。本研究拟通过骨髓间充质干细胞(MSCs)进行干预,观察能否提高造血干、祖细胞移植的植入率。方法: 应用贴壁培养法体外培养正常小鼠骨髓MSCs,并分为6个实验组,包括实验组1:d11 MSCs干预的致敏组;实验组2: d0 MSCs干预的致敏组;实验组3:d11和d0 2次MSCs干预的致敏组;实验组4: 无MSCs干预的致敏小鼠对照组;实验组5:无MSCs干预的正常小鼠(非致敏小鼠)移植对照组;实验组6:无MSCs干预的正常小鼠不移植对照组。观察指标包括生存分析、移植效果分析(血象改变、骨髓细胞恢复及嵌合分析等)和移植物抗宿主病(GVHD)检测,最终评估MSCs干预对各实验组异基因造血干/祖细胞移植植入率的影响效果。结果: 与对照组(实验组4、5、6)比较,MSCs干预(实验组1、2、3)在2次异基因脾细胞注射法致敏的动物模型进行异基因造血干/祖细胞移植时,未能促进骨髓造血干/祖细胞移植的植入,也未能延长致敏动物移植后的生存时间。结论: 体内应用1×10⁶ MSCs干预,未能促进2次异基因1×10⁶ C57BL/6小鼠脾细胞输注法建立的重度致敏模型异基因造血干/祖细胞移植的植入。     

Rapid thymic reconstitution following bone marrow transplantation in neonatal mice is VEGF-dependent

Age-related differences in thymic function influence the rapidity of T cell reconstitution following hematopoietic stem cell transplantation (HSCT). In adults, thymic reconstitution is delayed until after marrow engraftment is established, and is significantly improved by approaches that increase marrow chimerism, such as pretransplantation irradiation. In contrast, we show that neonatal mice undergo more rapid and efficient thymic reconstitution than adults, even when bone marrow (BM) engraftment is minimal and in the absence of pretransplantation radiation. We have previously shown that the neonatal thymus produces high levels of vascular endothelial growth factor (VEGF) that drives angiogenesis locally. In this report, we show that inhibition of VEGF prior to HSCT prevents rapid thymic reconstitution in neonates, but has no effect on thymic reconstitution in adults. These data suggest that the early radiation-independent thymic reconstitution unique to the neonatal host is mediated through VEGF, and reveals a novel pathway that might be targeted to improve immune reconstitution post-HSCT.     

Histopathological bone marrow changes after reduced-intensity hematopoietic stem cell transplantation for follicular lymphoma involving bone marrow

Allogeneic stem cell transplantation (allo-SCT) is used as curative therapy for malignant lymphoma, and reduced-intensity hematopoietic stem cell transplantation (RIST) is sometimes performed to avoid the toxicity and mortality associated with myeloablative allo-SCT. RIST is generally preferred for elderly patients with malignant lymphoma. A 62-year-old woman with follicular lymphoma (FL) involving bone marrow (BM) suffered relapse after autologous SCT. RIST was performed; cells were from an unrelated, fully human leukocyte antigen-matched donor. To study the hematopoietic reconstitution, BM biopsy specimens that were obtained at different times after RIST, were evaluated. Engraftment of donor cells was observed on days 19 and 48 after RIST, and residual FL in BM had completely disappeared by day 73 after RIST. This is the first report to document histological BM regeneration after RIST and disappearance of FL involving the BM.